Bayer Initiates Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients with Chronic Kidney Disease

Bayer starts Phase II ALPINE-1 study of BAY3283142, an sGC activator for chronic kidney disease, aiming to provide a new treatment option for cardiovascular diseases.